| Drug Type Small molecule drug | 
| Synonyms 2-Carba cyclic phosphatidic acid | 
| Target | 
| Action agonists, inhibitors | 
| Mechanism LPAR agonists(Lysophosphatidic acid receptors agonists), autotaxin inhibitors(Ectonucleotide pyrophosphatase/phosphodiesterase 2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1/2 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC22H41NaO5P | 
| InChIKeyLNGKSHJGHYPIQJ-KVVVOXFISA-N | 
| CAS Registry927880-40-8 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Osteoarthritis, Knee | Phase 2 | Taiwan Province  | 03 Nov 2022 | |
| Osteoarthritis | Preclinical | Japan  | 14 Jun 2017 | |
| Osteoarthritis | Preclinical | Japan  | 14 Jun 2017 | |
| Rheumatoid Arthritis | Preclinical | Japan  | 14 Jun 2017 | |
| Rheumatoid Arthritis | Preclinical | Japan  | 14 Jun 2017 | 





